Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Aromatase inhibitors].

M L Feutrie1, J Bonneterre

  • 1Hôpital civil d'Armentières, 112, rue Sadi-Carnot, 59285 Armentières.

Bulletin Du Cancer
|November 26, 1999
PubMed
Summary
This summary is machine-generated.

Aromatase inhibitors are crucial for breast cancer treatment, blocking estrogen production. Newer non-steroidal drugs like anastrozole and letrozole offer improved efficacy and tolerability compared to older treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-time reverse-transcription PCR to quantify a panel of 19 genes in breast cancer: relationships with sentinel lymph node invasion.

The International journal of biological markers·2017
Same author

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Analysis of Arrestin Recruitment to Chemokine Receptors by Bioluminescence Resonance Energy Transfer.

Methods in enzymology·2016
Same author

[Systemic treatment of brain metastases from breast cancer].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2015
Same author

A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

[What do clinicians do with the results of the systematic staging imaging at the time of the breast cancer diagnosis?].

Gynecologie, obstetrique & fertilite·2014
Same journal

[Update: Evolution in the management of metastatic urothelial carcinomas].

Bulletin du cancer·2026
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
See all related articles

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Aromatase inhibitors are vital in breast cancer therapy by blocking estrogen synthesis.
  • Two main classes exist: steroidal and non-steroidal inhibitors, differing in mechanism and specificity.

Purpose of the Study:

  • To review and compare the efficacy and tolerability of various aromatase inhibitors.
  • To highlight advancements in non-steroidal aromatase inhibitors for breast cancer treatment.

Main Methods:

  • Literature review of steroidal and non-steroidal aromatase inhibitors.
  • Comparative analysis of drug efficacy, specificity, and side effect profiles.

Main Results:

  • Aminoglutethimide and its analogue rogletimide show limited specificity and efficacy.

Related Experiment Videos

  • Newer non-steroidal inhibitors (letrozole, vorozole, exemestane, anastrozole) are more potent and specific.
  • Anastrozole, letrozole, and vorozole demonstrate comparable or superior efficacy and better tolerability than older agents in second-line therapy.

    • Conclusions:

    • Non-steroidal aromatase inhibitors represent a significant advancement in breast cancer treatment.
    • Letrozole, anastrozole, and vorozole are preferred for their improved efficacy and safety profiles, particularly in advanced stages.